News
  Date Title View
Dec 9, 2016
BURLINGTON, Mass., Dec. 09, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will provide a company overview at the BMO Capital Markets Prescriptions for Success Healthcare Conference on Wednesday, December 14, 2016 at 8:30 a.m. Eas...
Nov 16, 2016
BURLINGTON, Mass., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a price to the public of $18.00 per share.  The gross proceeds from this offering are expected to be approximately $64.8 mil...
Nov 15, 2016
BURLINGTON, Mass., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. Flexion also expects to grant the underwriters a 30-day option to purchase addi...
Nov 11, 2016
DALLAS, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that its lead investigational product candidate Zilretta (also known as FX006) demonstrated clinically and statistically significant improvements in an analysis of Phase 3 trial data conducted in patients with osteoarthritis (OA) o...
Nov 7, 2016
Successfully completed the transfer of the Zilretta™ manufacturing technology to Patheon - on track for NDA submission in December Met primary endpoint in clinical trial evaluating Zilretta in Type 2 diabetes patients with knee osteoarthritis ...
Nov 3, 2016
BURLINGTON, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that further analysis of Phase 3 data evaluating its investigational product, Zilretta™ (also known as FX006), in patients with osteoarthritis (OA) of the knee will be presented during the 26th American ...
Nov 1, 2016
-  Results Demonstrate a Markedly Lower Rise in Blood Glucose in Patients Receiving a Zilretta Injection Compared to Patients Receiving an Immediate- Release Triamcinolone Acetonide Injection  --  Difference was Both Statistically Significant and Clinically Relevant  ...
Oct 28, 2016
BURLINGTON, Mass., Oct. 28, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its third-quarter 2016 financial results on Monday, November 7, 2016, at 4:30 p.m. ET.The dial-in number for the conference call is 855-770-0022 for...
Sep 29, 2016
BURLINGTON, Mass., Sept. 29, 2016 (GLOBE NEWSWIRE) -- ...
Sep 14, 2016
BURLINGTON, Mass., Sept. 14, 2016 (GLOBE NEWSWIRE) -- ...
FirstPrevious
3
... NextLast
= add release to Briefcase